{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,23]],"date-time":"2026-02-23T02:34:19Z","timestamp":1771814059468,"version":"3.50.1"},"reference-count":18,"publisher":"Universa BV","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["AGEB"],"published-print":{"date-parts":[[2022,12]]},"abstract":"<jats:p>Background and study aim: Over the last 20 years, cytoreductive surgery (CRS) combined with hyperthermic intraperitoneal chemotherapy (HIPEC) has progressively become a therapeutic option for peritoneal carcinomatosis thanks to its favourable oncologic results. The aim of this study is to analyse the overall survival and recurrence-free survival, after complete CRS and closed abdomen technique HIPEC for peritoneal carcinomatosis from colorectal cancer.\n\nPatients and methods: This retrospective study collected the data from all patients who underwent a CRS with HIPEC for colorectal cancer at \u201cCliniques universitaires Saint Luc\u201d from October 2007 to December 2020. Ninety-nine patients were included.\n\nResults: The median follow-up was 34 months. Post-operative mortality and Clavien-Dindo grade III\/IV morbidity rates were 2.0% and 28.3%. The overall 2-year and 5-year survival rates were 80.1% and 54.4%. Using the multivariate analysis, age at surgery, liver metastases and PCI score &gt;13 showed a statistically significant negative impact on overall survival. The 2-year and 5-year recurrence-free survival rates were 33.9% and 22%. Using the multivariate analysis, it was found that liver metastases, the extent of carcinomatosis with PCI&gt;7 have a statistically significant negative impact on recurrence-free survival.\n\nConclusions: Despite a high recurrence rate, CRS followed by HIPEC to treat peritoneal carcinomatosis from colorectal origin offer encouraging oncologic results with a satisfying survival rate. When PCI&gt;13, CRS and HIPEC does not seem to offer any survival benefit and to efficiently limit recurrence, our data are in favor of a maximum PCI of 7.<\/jats:p>","DOI":"10.51821\/85.4.10811","type":"journal-article","created":{"date-parts":[[2023,1,5]],"date-time":"2023-01-05T20:03:10Z","timestamp":1672948990000},"page":"573-579","source":"Crossref","is-referenced-by-count":5,"title":["Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for peritoneal carcinomatosis from colorectal cancer: a 13 years-retrospective monocentric study"],"prefix":"10.51821","volume":"85","author":[{"given":"M","family":"Livin","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D","family":"Leonard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R","family":"Bachmann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C","family":"Remue","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S","family":"Barbois","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E","family":"Cotte","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M","family":"Van Den Eynde","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A","family":"De Cuyper","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"I","family":"Sinapi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A","family":"Van Maanen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A","family":"Kartheuser","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"27062","published-online":{"date-parts":[[2022,12]]},"reference":[{"key":"ref0","doi-asserted-by":"publisher","unstructured":"SEGELMAN J., GRANATH F., HOLM T., MACHADO M., MAHTEME H., MARTLING A. Incidence, prevalence and risk factors for peritoneal carcinomatosis from colorectal cancer. Br. J. Surg., 2012, 99: 699-705.","DOI":"10.1002\/bjs.8679"},{"key":"ref1","doi-asserted-by":"publisher","unstructured":"FRANKO J., SHI Q., MEYERS J.P., MAUGHAN T., ADAMS R., SEYMOUR M. et al. Prognosis of patients with peritoneal metastatic colorectal cancer given systemic therapy: an analysis of individual patient data from prospective randomised trials from the Analysis and Research in Cancers of the Digestive System (ARCAD) database. Lancet Oncol., 2016, 17: 1709-19.","DOI":"10.1016\/s1470-2045(16)30500-9"},{"key":"ref2","doi-asserted-by":"publisher","unstructured":"VERWAAL V.J., VAN RUTH S., DE BREE E., VAN SLOOTHEN G.W., VAN TINTEREN H., BOOT H. et al. Randomized trial of cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy and palliative surgery in patients with peritoneal carcinomatosis of colorectal cancer. J. Clin. Oncol., 2003, 21: 3737-43.","DOI":"10.1200\/jco.2003.04.187"},{"key":"ref3","doi-asserted-by":"publisher","unstructured":"ELIAS D., GILLY F., BOUTITIE F., QUENET F., BEREDER J.M., MANSVELT B. et al. Peritoneal colorectal carcinomatosis treated with surgery and perioperative intraperitoneal chemotherapy: retrospective analysis of 523 patients from a multicentric French study. J. Clin. Oncol., 2010, 28: 63-8.","DOI":"10.1200\/jco.2009.23.9285"},{"key":"ref4","doi-asserted-by":"publisher","unstructured":"GO\u00c9R\u00c9 D., MALKA D., TZANIS D., GAVA V., BOIGE V., EVENO C. et al. Is there a possibility of a cure in patients with colorectal peritoneal carcinomatosis amenable to complete cytoreductive surgery and intra-peritoneal chemotherapy? Ann. Surg., 2013, 257: 1065-71.","DOI":"10.1097\/sla.0b013e31827e9289"},{"key":"ref5","doi-asserted-by":"publisher","unstructured":"QUENET F., ELIAS D., ROCA L., GO\u00c9R\u00c9 D., GHOUTI L., POCARD M. et al. Cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy versus cytoreductive surgery alone for colorectal peritoneal metastases (PRODIGE 7): a multicentre, randomised, open-label, phase 3 trial. Lancet Oncol., 2021, 22: 256-66.","DOI":"10.1016\/s1470-2045(20)30599-4"},{"key":"ref6","doi-asserted-by":"publisher","unstructured":"COTTE E., PASSOT G., MOHAMED F, VAUDOYER D, GILLY FN, GLEHEN O. Management of peritoneal carcinomatosis from colorectal cancer: current state of practice. Cancer J., 2009, 15: 243-8.","DOI":"10.1097\/ppo.0b013e3181a58d67"},{"key":"ref7","doi-asserted-by":"publisher","unstructured":"JACQUET P., SUGARBAKER P.H. Clinical research methodologies in diagnosis and staging of patients with peritoneal carcinomatosis. Cancer Treat. Res., 1996, 82: 359-74.","DOI":"10.1007\/978-1-4613-1247-5_23"},{"key":"ref8","doi-asserted-by":"publisher","unstructured":"GLEHEN O., COTTE E., LIFANTE J.C., ARVIEUX C., MOLES N., BRIGAND C. et al. Peritoneal carcinomatosis in digestive cancers: cytoreductive surgery combined with intraperitoneal chemohyperthermia. The experience in Centre Hospitalier et Universitaire Lyon Sud (CHLS). Acta Chir. Belg., 2006, 106: 285-90.","DOI":"10.1080\/00015458.2006.11679894"},{"key":"ref9","doi-asserted-by":"publisher","unstructured":"GLEHEN O., MITHIEUX F., OSINSKY D., BEAUJARD A.C., FREYER G., GUERTSCH P. et al. Surgery combined with peritonectomy procedures and intraperitoneal chemohyperthermia in abdominal cancers with peritoneal carcinomatosis: a phase II study. J. Clin. Oncol., 2003, 21 : 799-806.","DOI":"10.1200\/jco.2003.06.139"},{"key":"ref10","doi-asserted-by":"publisher","unstructured":"QUENET F., GOERE D., MEHTA S.S., ROCA L., DUMONT F., HESSISSEN M. et al. Results of two bi-institutional prospective studies using intraperitoneal oxaliplatin with or without irinotecan during HIPEC after cytoreductive surgery for colorectal carcinomatosis. Ann. Surg., 2011, 254: 294-301.","DOI":"10.1097\/sla.0b013e3182263933"},{"key":"ref11","doi-asserted-by":"publisher","unstructured":"GO\u00c9R\u00c9 D., SOUADKA A., FARON M., CLOUTIER A., VIANA B., HONOR\u00c9 C. et al. Extent of Colorectal Peritoneal Carcinomatosis: Attempt to Define a Threshold Above Which HIPEC Does Not Offer Survival Benefit: A Comparative Study. Ann. Surg. Oncol., 2015, 22: 2958-2964.","DOI":"10.1245\/s10434-015-4387-5"},{"key":"ref12","doi-asserted-by":"publisher","unstructured":"ELIAS D., FARON M., GO\u00c9R\u00c9 D., DUMONT F., HONOR\u00c9 C., BOIGE V. et al. A Simple Tumor Load-Based Nomogram for Surgery in Patients with Colorectal Liver and Peritoneal Metastases. Ann. Surg. Oncol., 2014, 2: 2052- 2058.","DOI":"10.1245\/s10434-014-3506-z"},{"key":"ref13","doi-asserted-by":"publisher","unstructured":"YURTTAS C., HOFFMANN G., TOLIOS A., HAEN S., SCHWAB M., K\u00d6NIGSRAINER I. et al. Systematic review of variations in hyperthermic intraperitoneal chemoherapy (HIPEC) for peritoneal metastasis from colorectal caner. J. Clin. Med., 2018, 7: 567.","DOI":"10.3390\/jcm7120567"},{"key":"ref14","doi-asserted-by":"publisher","unstructured":"CAVALIERE F., DE SIMONE M., VIRZI S., DERACO M., ROSSI C.R., GAROFALO A. et al. Prognostic factors and oncologic outcome in 146 patients with colorectal peritoneal carcinomatosis treated with cytoreductive surgery combined with hyperthermic intraperitoneal chemotherapy: Italian multicenter study S.I.T.I.L.O. Eur. J. Surg. Oncol., 2011, 37: 148-54.","DOI":"10.1016\/j.ejso.2010.10.014"},{"key":"ref15","doi-asserted-by":"publisher","unstructured":"VAN DRIEL W.J., KOOLE S.N., SIKORSKA K., SCHAGEN VAN LEEUWEN J.H., SCHREUDER H.W.R., HERMANS R.H.M. et al. Hyperthermic intraperitoneal chemotherapy in ovarian cancer. N. Engl. J. Med., 2018, 378: 230-40.","DOI":"10.1056\/nejmoa1708618"},{"key":"ref16","doi-asserted-by":"publisher","unstructured":"REPULLO D.J., BARBOIS S., LEONARD D., BOHLOK A., VAN DEN AUDENAEREN E.T., DONCKIER V. et al. The absence of benefit of perioperative chemotherapy in initially resectable peritoneal metastases of colorectal cancer origin treated with complete cytoreductive surgery and hyperthermic intraperitoneal chemotherapy: A retrospective analysis. Eur. J. Surg. Oncol., 2021, 47: 1661-1667.","DOI":"10.1016\/j.ejso.2021.01.018"},{"key":"ref17","unstructured":"ROVERS K.P., BAKKERS C., NIENHUIJS S.W., BURGER J.W.A., CREEMERS G.M., THIJS A.M.J. et al Perioperative systemic therapy vs cytoreductive surgery and hyperthermic intraperitoneal chemotherapy alone for resectable colorectal peritoneal metastases, a Phase 2 Randomized Clinical Trial. JAMA Surg., 2021, 156: 710-720"}],"container-title":["Acta Gastro Enterologica Belgica"],"original-title":[],"language":"en","deposited":{"date-parts":[[2023,1,5]],"date-time":"2023-01-05T20:03:47Z","timestamp":1672949027000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ageb.be\/ageb-journal\/ageb-volume\/ageb-article\/2054\/Cytoreductive%20surgery%20and%20hyperthermic%20intraperitoneal%20chemotherapy%20for%20peritoneal%20carcinomatosis%20from%20colorectal%20cancer:%20a%2013%20years-retrospective%20monocentric%20study\/"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12]]},"references-count":18,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2022,6,21]]}},"URL":"https:\/\/doi.org\/10.51821\/85.4.10811","relation":{},"ISSN":["1784-3227"],"issn-type":[{"value":"1784-3227","type":"print"}],"subject":[],"published":{"date-parts":[[2022,12]]}}}